VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
December 19, 2017 08:00 ET
|
VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
December 11, 2017 07:30 ET
|
Mucodel Pharma LLC
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel...
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
December 08, 2017 10:27 ET
|
Amarantus Bioscience Holdings, Inc.
Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033 SAN FRANCISCO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based...
InspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
December 07, 2017 12:23 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 07, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
November 16, 2017 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
ETST and its wholly owned subsidiary, Cannabis Therapeutics, Signs Joint Venture with Smart Medicines GMP for the Development of its Cannabis Cannabinoid-Based Drugs & Nutraceuticals
February 14, 2017 07:15 ET
|
Earth Science Tech, Inc.
Hollywood, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid...
ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.
November 21, 2016 08:15 ET
|
Earth Science Tech, Inc.
Ft. Lauderdale, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and...
![murphy carolann](http://www.globenewswire.com/en/Attachment/LogoDisplay/416262?filename=416262.jpg&size=2)
Carolann Murphy Appointed to New Jersey Commission on Spinal Cord Research
November 08, 2016 10:31 ET
|
Kessler Foundation
EAST HANOVER, N.J., Nov. 8, 2016 (GLOBE NEWSWIRE) -- Carolann Murphy, PA, was appointed to the New Jersey Commission on Spinal Cord Research by Governor Chris Christie. Murphy will serve a three-year...
![Kessler Foundation logo](/news-release/logo/391548/0/391548.jpg?lastModified=12%2F09%2F2016%2022%3A54%3A18&size=2)
Carolann Murphy Appointed to New Jersey Commission on Spinal Cord Research
November 07, 2016 14:58 ET
|
Kessler Foundation
EAST HANOVER, N.J., Nov. 7, 2016 (GLOBE NEWSWIRE) -- Carolann Murphy, PA, was appointed to the New Jersey Commission on Spinal Cord Research by Governor Chris Christie. Murphy will serve a three-year...
![Kirshblum_110211_14_6x4](http://www.globenewswire.com/en/Attachment/LogoDisplay/415001?filename=415001.jpg&size=2)
Kessler Foundation Awarded $2.3 Million Spinal Cord Injury Model System Grant
November 01, 2016 13:05 ET
|
Kessler Foundation
EAST HANOVER, N.J., Nov. 1, 2016 (GLOBE NEWSWIRE) -- Kessler Foundation has been awarded a Spinal Cord Injury Model System (SCIMS) grant valued at $2,300,000 over 5 years (2016-2021) from the National...